MR antagonists reduced mortality and morbidity rates in patients with HF in large clinical studies (RALES, EPHESUS and EMPHASIS-HF trials [49–51]) and are commonly used as a standard treatment for patients with HF. The gene discussed is NR3C2; the disease is hydrops fetalis.